The Centers for Medicare & Medicaid Services today finalized a new Center for Medicare and Medicaid Innovation payment model aimed at transforming kidney care to ensure patients with chronic kidney disease have access to high quality, coordinated care.

The End-Stage Renal Disease Treatment Choices model will be mandatory for dialysis facilities and managing clinicians in certain areas of the country beginning Jan. 1, and test whether greater use of home dialysis and kidney transplantation for Medicare beneficiaries with ESRD reduce expenditures while preserving or enhancing quality of care.

The model’s payment adjustments will begin in January and run through June 30, 2027.

Related News Articles

Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The House Ways and Means Committee today advanced its portion of the fiscal year 2025 reconciliation bill by a 26-19 vote along party lines, following an hours…
Headline
The House Ways and Means Committee May 13 began to mark up its portion of the fiscal year 2025 reconciliation bill, with some proposals impacting the health…